Evista raloxifene regulatory update

The U.S. Preventive Services Task Force (USPSTF) released a final guideline recommending the use of raloxifene and tamoxifen to lower the risk of primary breast cancer in women who are at increased risk for breast cancer and at low risk for adverse medication effects. However, the USPSTF recommended against the routine use of the drugs to reduce the risk of primary breast cancer in women who are not at increased risk for breast cancer. The recommendations reaffirm USPSTF's 2002 recommendations for use of the products to prevent breast cancer. ...